Earnings Outlook: Biogen earnings: It’s all about upcoming Alzheimer’s disease results

When drugmaker Biogen Inc. releases third-quarter earnings, scheduled for before the open on Tuesday, other major events for the company could well overshadow the financials.

Chief among them is the company’s upcoming Alzheimer’s disease results, for the buzzed-about therapy BAN2401, which Biogen BIIB, -1.71% and partner Eisai 4523, -1.95% are set to present at an European conference this week.

Call it financial déjà vu: The last time BAN2401 results were coming up, around Biogen’s second-quarter earnings, Wall Street analysts spent much of the company’s conference call asking about the trial.

See Also

>>> Original Source <<<